hotspot -WSS

hotspot

author：focus 2025-09-29 13:09:55 - browse：73

Is Wegovy the future of cardiology? Can Novo Nordisk ever make enough of it? And will there ever be an Apple of pharma?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. In the wake of a massively important clinical trial of Novo Nordisk’s obesity drug Wegovy, our colleague Elaine Chen joins us to explain what we know and don’t know about data that could change the practice of medicine. Then, Mizuho Securities biotech strategist Jared Holz calls in to discuss whether explosive popularity of obesity treatments could help create the first trillion-dollar drug company.

For more on what we cover, here’s the news on the Wegovy study; here’s more on its implications; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical records are filled with copy
Next article： Why scientists need input from humanists on sensitive research

WSS

Medtronic CEO on promising devices for diabetes, hypertension

Male and female sex labels in research insufficient, scientists say

Senate panel to vote on hospitals, PBMs, prisoner care

As AI in medicine takes off, can 'human in the loop' prevent harm?

Senate panel to vote on hospitals, PBMs, prisoner care

Telehealth options flood the market as retailers push virtual care

leisure time

hotspot

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: XBI biotech index, Akero Therapeutics

New air purifier tech could be key to improving indoor air quality

Male and female sex labels in research insufficient, scientists say

BioMarin wins approval for gene therapy to treat hemophilia A

Cassava reveals details — and problems — with Alzheimer's study

State Dept. review finds Biden bears some blame for Afghanistan failures

Medicare coverage of Wegovy, once blocked, now looks possible

Continuity nursing helped my family in our darkest PICU moments

As AI in medicine takes off, can 'human in the loop' prevent harm?

hotspot

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

The pink breast cancer awareness ribbon needs a redesign

Medicare coverage of Wegovy, once blocked, now looks possible

Testing for cancer recurrence creates a new limbo for patients

Why Sanofi got shellacked over its spinoff

Why scientists need input from humanists on sensitive research

focus

entertainment

explore

focus